United States - English - NLM (National Library of Medicine)

a-s medication solutions - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+ 40iu/0.5ml+ 25/25mcg/0.5ml+ 40/8/32 du/0.5ml+ 10mcg/0.5ml+ 12mcg/0.5ml+ 22-36mcg/0.5ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi pasteur sa - diphtheria toxoid, tetanus toxoid, pertussis toxoid/filamentous haemagglutinin, poliovirus types 1/2/3, hepatitis b surface antigen, haemophilus infuenzae type b polysaccharide, haemophilus infuenzae type b polysaccharide conjugated to tetanus protein - suspension for injection - 20iu/0.5ml+ 40iu/0.5ml+ 25/25mcg/0.5ml+ 40/8/32 du/0.5ml+ 10mcg/0.5ml+ 12mcg/0.5ml+ 22-36mcg/0.5ml

European Union - English - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vaccines - active immunisation against disease caused by streptococcus pneumoniae serotypes 4, 6b, 9v, 14, 18c, 19f and 23f (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from two months up to five years of age.the use of prevenar should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as variability of serotype epidemiology in different geographical areas.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenzae type-b.

Canada - English - Health Canada

sanofi pasteur limited - meningococcal group a polysaccharide-tetanus toxoid conjugate; meningococcal group c polysaccharide-tetanus toxoid conjugate; meningococcal group y polysaccharide-tetanus toxoid conjugate; meningococcal group w polysaccharide-tetanus toxoid conjugate; tetanus toxoid - solution - 10mcg; 10mcg; 10mcg; 10mcg; 55mcg - meningococcal group a polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group c polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group y polysaccharide-tetanus toxoid conjugate 10mcg; meningococcal group w polysaccharide-tetanus toxoid conjugate 10mcg; tetanus toxoid 55mcg - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - meningococcal polysaccharide - group c; tetanus toxoid; aluminium hydroxide; meningococcal group c polysaccharide; meningococcal group c polysaccharide -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pneumococcal polysaccharide serotype 14 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 18c 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 19f 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 23f 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 4 2ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 6b 4ug (conjugated with diphtheria crm 197 protein); pneumococcal polysaccharide serotype 9v 2ug (conjugated with diphtheria crm 197 protein) - suspension for injection - 0.5 ml - active: pneumococcal polysaccharide serotype 14 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 18c 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 19f 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 23f 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 4 2ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 6b 4ug (conjugated with diphtheria crm 197 protein) pneumococcal polysaccharide serotype 9v 2ug (conjugated with diphtheria crm 197 protein) excipient: aluminium phosphate sodium chloride water for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - diphtheria toxoid adsorbed tetanus toxoid adsorbed pertussis toxoid adsorbed (pt) filamentous haemagglutinin adsorbed (fha) fimbriae types 2 and 3 adsorbed (fim) pertactin adsorbed (prn) inactivated poliomyelitis vaccine type 1 (mahoney) inactivated poliomyelitis vaccine type 2 (mef-1) inactivated poliomyelitis vaccine type 3 (saukett) haemophilus influenzae b conjugate vaccine (prp-t) conjugated to tenanus protein aluminium phosphate (a1) - suspension for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis vaccines & diagnostics pty ltd - meningococcal oligosaccharide - group w135; meningococcal oligosaccharide - group c; meningococcal oligosaccharide - group a; diphtheria crm197 protein; meningococcal oligosaccharide - group y -